- PhD student; MSc
- +47 2278 1957
The primary objective of the PhD project is to develop a new approach to personalized cancer therapy. Differently from other approaches, a transdisciplinary strategy will be applied to implement today’s cancer therapy. The project aims to establish a new pipeline to identify drugs and drug combinations effective in personalized therapy of individual cancer patients, in whom other treatment options are exhausted or ineffective. Novel in-silico mathematical models and simulations will also be applied to investigate the current challenges of tumor heterogeneity and drug resistance mechanisms.
To date, ex vivo drug sensitivity and resistance testing are performed in our lab, with patient cancer cells and patient-derived cell lines for multiple myeloma (MM) and chronic lymphatic leukemia (CLL). The drug sensitivity responses are measured by cell viability and death readouts along with relevant cell signaling analysis.
Ex vivo drug sensitivity screening in multiple myeloma identifies drug combinations that act synergistically
Mol Oncol, 16 (6), 1241-1258
Mcl-1 and Bcl-xL levels predict responsiveness to dual MEK/Bcl-2 inhibition in B-cell malignancies
Mol Oncol, 16 (5), 1153-1170
Drug Sensitivity Screening on Multiple Myeloma for Precision Cancer Therapy
Blood, 132, 4677
Hypoxia promotes IL-32 expression in myeloma cells, and high expression is associated with poor survival and bone loss
Blood Adv, 1 (27), 2656-2666